DNA markers to predict chemo response in advanced colon cancer
Part of Cancer, Digestive system clinical trials.
This study uses a blood test to look for specific DNA changes that may help predict how well chemotherapy works in people with metastatic colorectal cancer. The goal is to find markers that could guide future treatment decisions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have metastatic colorectal cancer that has spread beyond the colon.
- You have already received first-line chemotherapy with FOLFOX or FOLFIRI.
- You have stored blood samples taken before treatment that can be tested.
- Your doctor has documented how your tumor responded to treatment (using scans or progression-free survival).
- Your tumor has been tested for RAS and BRAF gene mutations.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is developing a blood test that looks at DNA signals to see if certain targeted therapies will work for people with metastatic colorectal cancer. It may help doctors choose the right treatment in the future.
This trial tests whether adjusting treatment based on a simple blood test (circulating tumor DNA) after two cycles of chemo can be safe and effective for people with advanced colorectal cancer. The goal is to tailor therapy to each person's response.
This trial checks a blood test for “ctDNA methylation” to see who may be at higher risk of colorectal cancer returning after surgery. It may help doctors better judge whether adjuvant chemotherapy is working or needed.
This study looks at whether a blood test for tumor DNA (ctDNA) can predict how well immunotherapy works in people with advanced or locally advanced colorectal cancer that has specific genetic features (dMMR/MSI-H). If you qualify, the trial will monitor your ctDNA levels while you receive standard immunotherapy to see if changes in those levels can show early on if the treatment is working.
This study uses a blood test to check for tumor DNA after surgery, which may help doctors decide if you need additional chemotherapy. It is for people with stage 3 colorectal cancer that is removed by surgery.
This study tests whether a simple blood test can track how well your colorectal cancer is responding to first-line chemotherapy. By monitoring cancer markers in your blood, doctors may be able to detect treatment changes earlier than traditional imaging.
Hear when a new CRC (Colorectal Cancer) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.